Neil A O'brien

Title(s)Associate Adjunct Professor, Medicine
SchoolMedicine
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Res. 2020 08 14; 22(1):89. O'Brien NA, McDermott MSJ, Conklin D, Luo T, Ayala R, Salgar S, Chau K, DiTomaso E, Babbar N, Su F, Gaither A, Hurvitz SA, Linnartz R, Rose K, Hirawat S, Slamon DJ. PMID: 32795346.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    2. EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells. Mol Cancer Ther. 2020 08; 19(8):1682-1695. Dillard C, Kiyohara M, Mah V, McDermott SP, Bazzoun D, Tsui J, Chan AM, Haddad G, Pellegrini M, Chang YL, Elshimali Y, Wu Y, Vadgama JV, Kim SR, Goodglick L, Law SM, Patel DD, Dhawan P, O'Brien NA, Gordon LK, Braun J, Lazar G, Wicha MS, Wadehra M. PMID: 32451329.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    3. Role for polo-like kinase 4 in mediation of cytokinesis. Proc Natl Acad Sci U S A. 2019 06 04; 116(23):11309-11318. Press MF, Xie B, Davenport S, Zhou Y, Guzman R, Nolan GP, O'Brien N, Palazzolo M, Mak TW, Brugge JS, Slamon DJ. PMID: 31097597.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    4. Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo. . 2019 06; 18(6):1115-1126. Zoeller JJ, Vagodny A, Taneja K, Tan BY, O'Brien N, Slamon DJ, Sampath D, Leverson JD, Bronson RT, Dillon DA, Brugge JS. PMID: 30962322.
      View in: PubMed   Mentions:
    5. HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells. Cancers (Basel). 2019 Feb 08; 11(2). McDermott MSJ, Conlon N, Browne BC, Szabo A, Synnott NC, O'Brien NA, Duffy MJ, Crown J, O'Donovan N. PMID: 30743996.
      View in: PubMed   Mentions:
    6. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. BMC Cancer. 2018 Oct 11; 18(1):965. Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J. PMID: 30305055.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    7. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer. Invest New Drugs. 2019 06; 37(3):441-451. Canonici A, Ivers L, Conlon NT, Pedersen K, Gaynor N, Browne BC, O'Brien NA, Gullo G, Collins DM, O'Donovan N, Crown J. PMID: 30062574.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    8. MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer. . 2018 07; 17(7):1430-1440. Koutsioumpa M, Chen HW, O'Brien N, Koinis F, Mahurkar-Joshi S, Vorvis C, Soroosh A, Luo T, Issakhanian S, Pantuck AJ, Georgoulias V, Iliopoulos D, Slamon DJ, Drakaki A. PMID: 29703843.
      View in: PubMed   Mentions:
    9. Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer. . 2018 05; 17(5):897-907. O'Brien N, Conklin D, Beckmann R, Luo T, Chau K, Thomas J, Mc Nulty A, Marchal C, Kalous O, von Euw E, Hurvitz S, Mockbee C, Slamon DJ. PMID: 29483214.
      View in: PubMed   Mentions:
    10. The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells. Invest New Drugs. 2018 08; 36(4):581-589. Canonici A, Qadir Z, Conlon NT, Collins DM, O'Brien NA, Walsh N, Eustace AJ, O'Donovan N, Crown J. PMID: 29396630.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    11. Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells. Int J Oncol. 2017 Jun; 50(6):2221-2228. McDermott MSJ, Canonici A, Ivers L, Browne BC, Madden SF, O'Brien NA, Crown J, O'Donovan N. PMID: 28498399.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    12. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. Breast Cancer Res Treat. 2015 Feb; 149(3):669-80. Hurvitz SA, Kalous O, Conklin D, Desai AJ, Dering J, Anderson L, O'Brien NA, Kolarova T, Finn RS, Linnartz R, Chen D, Slamon DJ. PMID: 25663547.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    13. PP2A inhibition overcomes acquired resistance to HER2 targeted therapy. Mol Cancer. 2014 Jun 24; 13:157. McDermott MS, Browne BC, Conlon NT, O'Brien NA, Slamon DJ, Henry M, Meleady P, Clynes M, Dowling P, Crown J, O'Donovan N. PMID: 24958351.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    14. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res. 2014 Jul 01; 20(13):3507-20. O'Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz R, Finn RS, Hirawat S, Slamon DJ. PMID: 24879796.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCells
    15. PIAS1 regulates breast tumorigenesis through selective epigenetic gene silencing. PLoS One. 2014; 9(2):e89464. Liu B, Tahk S, Yee KM, Yang R, Yang Y, Mackie R, Hsu C, Chernishof V, O'Brien N, Jin Y, Fan G, Lane TF, Rao J, Slamon D, Shuai K. PMID: 24586797.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    16. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013 Oct; 4(10):1592-605. Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, Crown J, Kong A. PMID: 24009064.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimalsCells
    17. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. . 2013 May; 12(5):632-42. Konecny GE, Kolarova T, O'Brien NA, Winterhoff B, Yang G, Qi J, Qi Z, Venkatesan N, Ayala R, Luo T, Finn RS, Kristof J, Galderisi C, Porta DG, Anderson L, Shi MM, Yovine A, Slamon DJ. PMID: 23443805.
      View in: PubMed   Mentions:
    18. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. . 2013 Apr; 12(4):509-19. Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, Ayala R, O'Brien NA, Quadt C, Akimov M, Slamon DJ, Finn RS. PMID: 23395886.
      View in: PubMed   Mentions:
    19. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. Breast Cancer Res Treat. 2012 Dec; 136(3):717-27. Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, McDermott MS, Larkin A, Ballot J, Mahgoub T, Sclafani F, Madden S, Kennedy J, Duffy MJ, Crown J, O'Donovan N. PMID: 23117852.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    20. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. . 2012 Sep; 11(9):1978-87. Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS. PMID: 22761403.
      View in: PubMed   Mentions:
    21. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev. 2013 May; 39(3):219-29. Hurvitz SA, Hu Y, O'Brien N, Finn RS. PMID: 22658319.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimals
    22. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. . 2010 Jun; 9(6):1489-502. O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ. PMID: 20501798.
      View in: PubMed   Mentions:
    23. Use of a panel of novel genes for differentiating breast cancer from non-breast tissues. Tumour Biol. 2007; 28(6):312-7. O'Brien N, O'Donovan N, Foley D, Hill AD, McDermott E, O'Higgins N, Duffy MJ. PMID: 18253069.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    24. Lipophilin B: A gene preferentially expressed in breast tissue and upregulated in breast cancer. Int J Cancer. 2007 Mar 01; 120(5):1087-92. Culleton J, O'Brien N, Ryan BM, Hill AD, McDermott E, O'Higgins N, Duffy MJ. PMID: 17163411.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    25. Mammaglobin a in breast cancer: existence of multiple molecular forms. Int J Cancer. 2005 Apr 20; 114(4):623-7. O'Brien NA, O'Donovan N, Ryan B, Hill AD, McDermott E, O'Higgins N, Duffy MJ. PMID: 15609337.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    26. Mammaglobin a: a promising marker for breast cancer. Clin Chem. 2002 Aug; 48(8):1362-4. O'Brien N, Maguire TM, O'Donovan N, Lynch N, Hill AD, McDermott E, O'Higgins N, Duffy MJ. PMID: 12142396.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    Neil's Networks
    Concepts (160)
    Derived automatically from this person's publications.
    _
    Co-Authors (16)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _